Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes
Jun 17, 2024
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes
Apr 19, 2024
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
Jun 07, 2023
Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO
Jan 11, 2022
Amarna Therapeutics and Redoxis receive EUREKA Eurostars grant to establish a screening platform for the advancement of a potential first-in-class gene therapy for ALS and other neurodegenerative diseases
Dec 01, 2021
Amarna Therapeutics secures additional €5 ($5.7) million to advance its transformative gene therapy platform towards clinical trials
Oct 30, 2020
Amarna Therapeutics Appoints Kite Pharma Veteran Dr. Markwin Velders to its Supervisory Board
Sep 25, 2020
Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVecTM gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis
Sep 03, 2020
Amarna Therapeutics Announces the Appointment of Steen Klysner as Chief Executive Officer
Oct 16, 2019
Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board web developer when laying out the website
